Until now, every Bitcoin Improvement Proposal (BIP) that needed cryptographic primitives had to reinvent the wheel. Each one ...

Recursion announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractory B-cell lymphomas. EXCELERIZE, the ...

Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary ...

After all, market upheaval is no reason to abandon a long-term investing plan, assuming that investing plan was thoughtfully constructed in the first place. Billy Duberstein and/or his clients ...

Sen. Dick Durbin (D-Ill.), the No. 2 Senate Democrat, announced Wednesday he will not seek reelection, capping off a decades-long Senate career. “The decision of whether to run for reelection ...

John Authers is a senior editor for markets and Bloomberg Opinion columnist. A former chief markets commentator at the Financial Times, he is author of “The Fearful Rise of Markets.” Global ...

Recursion Pharmaceuticals uses artificial intelligence ... that could mean more shareholder dilution. Therefore, it's no surprise to see these stocks sell off hard today. But as with most of ...

Now we know the real reason Michelle Obama wasn’t at Trump’s inauguration: She has started practicing “the art of saying ‘no.’” And that meant opting out of the “hypocrisy and ...